Table 2.

Incidence rates of serious infection, composite CVD, and non-vertebral osteoporotic fracture within 365 days after initiation denosumab and zoledronic acid in the propensity score matched cohort

	Denosumab N=2,467			Zoledronic acid N=2,467
	Cases	Person years	IR*(95% CI)	Cases	Person years	IR*(95% CI)	IRR† (95% CI)
Serious infection	42	1,618	25.96 (18.97-34.73)	62	1,994	31.1 (24.06-39.58)	0.83 (0.56-1.23)
Composite CVD	20	1,627	12.29 (7.74-18.61)	22	2,012	10.93 (7.05-16.25)	1.12 (0.61-2.05)
Myocardial infarction	3	1,635	1.83 (0.51-4.90)	3	2,021	1.48 (0.41-3.96)	1.24 (0.25-6.14)
Stroke	1	1,636	0.61 (0.06-2.85)	4	2,020	1.98 (0.66-4.71)	0.31 (0.03-2.77)
Coronary revascularization	5	1,634	3.06 (1.16-6.71)	7	2,019	3.47 (1.55-6.81)	0.88 (0.28-2.77)
Heart failure	14	1,629	8.59 (4.92-14.03)	11	2,018	5.45 (2.89-9.43)	1.58 (0.72-3.48)
Non-vertebral osteoporotic fracture	60	1,606	37.36 (28.78-47.74)	58	1,988	29.17 (22.37-37.43)	1.28 (0.89-1.84)

CI=confidence interval; IR=incidence rate; IRR=incidence rate ratio

^*Per 1,000 person-years

^†Zoledronic acid users were the reference group